Clinical trials: Advanced Stage Solid Tumors
Solid Tumor
A Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
This is a phase 1/2 multicenter, first-in-human study of IBI129. It includes a phase 1 dose escalation and expansion section to identify MTD/RP2D of IBI129, plan to enroll 22~180 subjects, and a phase 2 to explore efficacy…
- Trial name
- NCT05991349
- Testing
- IBI129
- Where
- 7 sites in Australia, China
- Volunteers
- 36 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Locally Advanced Tumors, Metastatic Solid Tumors
A Study of DCC-2701 in Participants With Advanced Solid Tumors
The main purpose of this study is to investigate the safety of the investigational drug DCC-2701 and whether it will work to help people who have advanced solid tumors or cancer that has spread to other parts of the body.
- Conditions
- Locally Advanced Tumors, Metastatic Solid Tumors, Cancers With MET Genomic Alterations, Cancers With TRK Genomic Alterations
- Trial name
- NCT02228811
- Testing
- DCC-2701 tablet
- Where
- 5 sites in United States
- Volunteers
- 44 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Advanced Solid Tumor, Non Small Cell Lung Cancer
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC, 1st Line NSCLC
- Trial name
- SYNERGY-101 (NCT05098132)
- Testing
- STK-012, pembrolizumab KEYTRUDA®, pemetrexed
- Where
- 47 sites in United States, Georgia and 2 more
- Volunteers
- 364 people
- Sponsor
- Synthekine
Advanced Solid Tumor
A Phase I Trial of Simmitinib in Advanced Solid Tumors
This is an open label, multi-center, phase I study of oral Simmitinib in subjects with advanced solid tumors including gastric cancer.
- Trial name
- NCT04058587
- Testing
- Simmitinib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Advanced Solid Tumor
A Dose Escalation and Expansion Study of NB002 in Participants With Advanced or Metastatic Solid Tumors
This study is a first-in-human, multicenter, open label, uncontrolled, non-randomized, phase 1a/1b study, to evaluate the safety, tolerability, and preliminary antitumor activity of NB002 in subjects with advanced solid tumors.
- Trial name
- NCT05924906
- Testing
- NB002
- Volunteers
- 30 people
- Sponsor
- Suzhou Neologics Bioscience Co., Ltd.
Neoplasms
A Study of RO5045337 [RG7112] in Patients With Advanced Solid Tumors
This study will determine the maximum tolerated dose and the optimal associated 4 weekly dosing schedule of RO5045337, administered as monotherapy in patients with advanced solid tumors.
- Trial name
- NCT00559533
- Testing
- RO5045337
- Where
- 7 sites in United States, France
- Volunteers
- 106 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer, Lung Cancer
Ontario-wide Cancer TArgeted Nucleic Acid Evaluation
Substantial progress has been made in the treatment of cancer through the use of targeted therapies, but what works for one patient might not work for another patient.
- Conditions
- Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma
- Trial name
- OCTANE (NCT02906943)
- Where
- 7 sites in Canada
- Volunteers
- 10,000 people
- Sponsor
- University Health Network, Toronto
Lymphoma, Cancer
Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies
The purpose of this study is to determine the best and safest dose of XL184 administered orally. XL184 is a new chemical entity that inhibits VEGFR2, MET and RET, kinases implicated in tumor formation, growth and migration.
- Conditions
- Lymphoma, Cancer, Thyroid Carcinoma
- Trial name
- NCT00215605
- Testing
- XL184
- Where
- 5 sites in United States
- Volunteers
- 85 people
- Sponsor
- Exelixis
Advanced Solid Tumors
AT1019 Plus SBRT and PD-1 Inhibitor for Advanced Solid Tumors: An IIT Study
The goal of this clinical trial is to assess the safety and tolerability of AT1019 when used in combination with SBRT and PD-1 inhibitor, and determine the maximum tolerated dose (MTD) of AT1019 in the combination therapy of SBRT…
- Trial name
- NCT07285395
- Testing
- AT1019
- Where
- China
- Volunteers
- 12 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Advanced Solid Tumors or Lymphomas
A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas
CA-170 is a rationally designed and orally available, small molecule that directly targets the Programmed death-ligands 1 and 2 (PD-L1/PD-L2), and V-domain Ig suppressor of T cell activation (VISTA) immune checkpoints and results…
- Trial name
- NCT02812875
- Testing
- CA-170
- Where
- 20 sites in United States, South Korea and 2 more
- Volunteers
- 71 people
- Sponsor
- Curis, Inc.
Solid Tumor, Adult, Advanced Solid Tumor
A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors
This is a Phase 1/1b open-label, dose-escalation, and cohort expansion study with BID (tablet) oral dose of MPT-0118 in subjects with advanced or metastatic refractory solid tumors.
- Conditions
- Solid Tumor, Adult, Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer
- Trial name
- NCT04859777
- Testing
- MPT-0118, MPT-0118 + pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 70 people
- Sponsor
- Monopteros Therapeutics Inc.
Solid Tumor
Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors
SYD985.004 is a two-part phase I study with the antibody-drug conjugate SYD985 in combination with niraparib aimed at evaluating safety, pharmacokinetics and efficacy in patients with HER2-expressing locally advanced or…
- Trial name
- NCT04235101
- Testing
- SYD985 + Niraparib
- Where
- 6 sites in Belgium, Netherlands and 1 more
- Volunteers
- 32 people
- Sponsor
- Byondis B.V.
Locally Advanced or Metastatic Solid Tumors, Squamous-cell Non-small Cell Lung Cancer
HLX35(EGFR×4-1BB Bispecific) in Patients With Advanced or Metastatic Solid Tumors
This Phase1, multicenter, first-in-human, open-label, dose-escalation, and dose expansion study will evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor efficacy of HLX35 administered as a single-agent…
- Trial name
- NCT05360381
- Testing
- HLX35
- Where
- 2 sites in China
- Volunteers
- 82 people
- Sponsor
- Shanghai Henlius Biotech
KRAS G12C Mutant Advanced Solid Tumors
A Study of ZG19018 in Patients With KRAS G12C Mutant Advanced Solid Tumors.
Evaluate the safety and tolerability of ZG19018 in Patients with KRAS G12C mutant advanced solid tumors.
- Trial name
- NCT06237400
- Testing
- ZG19018
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Tumors
A Dose-escalation Study of BIBF 1120 in Japanese Patients With Advanced Solid Tumours
Confirmation of BIBF 1120 administered from 150 mg twice daily (b.i.d.) to 250 mg b.i.d. as safe and tolerable treatment in Japanese patients with advanced solid tumours, overall safety, pharmacokinetic parameters, biomarkers…
- Trial name
- NCT02182128
- Testing
- BIBF 1120
- Volunteers
- 24 people
- Sponsor
- Boehringer Ingelheim
Solid Tumor
Dose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF and/or NRAS Mutations
This is an open-label, Phase 1, dose escalation study of oral ARQ 736 administered to subjects with advanced solid tumors harboring the mutation.
- Trial name
- NCT01225536
- Testing
- ARQ 736
- Where
- 4 sites in United States, Italy
- Volunteers
- 24 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Advanced Solid Tumours
AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer
This is a phase Ib/II, open-label multicentre study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of AZD9150 plus durvalumab alone or in combination with chemotherapy in patients with…
- Trial name
- NCT03421353
- Testing
- AZD9150, Durvalumab, Cisplatin
- Where
- 6 sites in United States
- Volunteers
- 76 people
- Sponsor
- AstraZeneca
Solid Tumors
Safety and Pharmacokinetics of BPI-9016M in Patients With Advanced Solid Tumors
BPI-9016M is a novel, highly potent and selective small-molecule inhibitor of c-Met/Axl kinase. In preclinical studies, it demonstrated strong activity in vitro and in vivo against c-Met/Axl kinase and its downstream signaling…
- Trial name
- NCT02478866
- Testing
- BPI-9016M
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Solid Tumor, Adult
Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors
This is a Phase Ib/II study to assess the safety, tolerability and preliminary efficacy of AK119 combined with AK112 in patients with advanced solid tumors.
- Trial name
- NCT05689853
- Testing
- AK119, AK112
- Where
- China
- Volunteers
- 87 people
- Sponsor
- Akeso
Solid Tumor (Phase I)
A Phase I Study of ABSK211 in Participants With Advanced Solid Tumors With KRAS Alteration
This is a first-in-human (FIH), multicenter, open-label, phase I study of ABSK211 in participants with advanced solid tumors to evaluate safety, tolerability, PK and optimize the dosage.
- Trial name
- NCT07718165
- Testing
- ABSK211
- Where
- China
- Volunteers
- 247 people
- Sponsor
- Abbisko Therapeutics Co, Ltd